Immunosuppression with chlorambucil, versus placebo, for scleroderma. Results of a three-year, parallel, randomized, double-blind study.

Placebo and chlorambucil (0.05-0.1 mg/kg/day) were compared as treatments for scleroderma in a 3-year, randomized, double-blind, parallel study of 65 patients. Slopes of change over time, calculated for each organ system of each patient, failed to show significant differences between treatment groups. An immunosuppressive effect in the chlorambucil-treated group was shown by decreases in the white blood cell counts (P = 0.02), platelet counts (P = 0.04), lymphocyte counts (P = 0.001), IgA/IgM concentrations (P less than or equal to 0.05), and wheal size on mumps skin tests (P = 0.02). Three years of immunosuppressive treatment with chlorambucil did not benefit this scleroderma population.

[1]  J. Weiss,et al.  Reversible cold-induced abnormalities in myocardial perfusion and function in systemic sclerosis. , 1986, Annals of internal medicine.

[2]  E. Skopińska-Różewska,et al.  Modulatory effect of sera from scleroderma patients on lymphocyte-induced angiogenesis. , 1985, Arthritis and rheumatism.

[3]  M. Sabbadini,et al.  Antinuclear antibodies in progressive systemic sclerosis. , 1985, Clinical and experimental rheumatology.

[4]  H. Paulus,et al.  Clinical and serological comparison of 17 chronic progressive systemic sclerosis (PSS) and 17 CREST syndrome patients matched for sex, age, and disease duration. , 1984, Annals of the rheumatic diseases.

[5]  T. Whiteside,et al.  Products of activated mononuclear cells modulate accumulation of collagen by normal dermal and scleroderma fibroblasts in culture. , 1984, The Journal of laboratory and clinical medicine.

[6]  H. Paulus,et al.  Case control study of antibodies to ENA in progressive systemic sclerosis patients. , 1984, The Journal of rheumatology.

[7]  T. Whiteside,et al.  Lymphocytes in the skin of patients with progressive systemic sclerosis. Quantification, subtyping, and clinical correlations. , 1984, Arthritis and rheumatism.

[8]  T. Whiteside,et al.  Suppressor cell function and T lymphocyte subpopulations in peripheral blood of patients with progressive systemic sclerosis. , 1983, Arthritis and rheumatism.

[9]  T. Medsger,et al.  Immune complexes in progressive systemic sclerosis (scleroderma). , 1982, Arthritis and rheumatism.

[10]  E. Leroy,et al.  Pathogenesis of scleroderma (systemic sclerosis). , 1982, The Journal of investigative dermatology.

[11]  M. Kahaleh,et al.  Elevated levels of circulating platelet aggregates and beta-thromboglobulin in scleroderma. , 1982, Annals of internal medicine.

[12]  D. Furst,et al.  Abnormalities of pulmonary vascular dynamics and inflammation in early progressive systemic sclerosis. , 1981, Arthritis and rheumatism.

[13]  A. Scherbel,et al.  Abnormalities of immunoregulation in progressive systemic sclerosis. Evidence for excess helper-cell function and altered B-cell function. , 1981, Archives of dermatology.

[14]  A. Masi.  Preliminary criteria for the classification of systemic sclerosis (scleroderma). , 1980, Bulletin on the rheumatic diseases.

[15]  S. Young,et al.  Development of a scleroderma-like illness during therapy with L-5-hydroxytryptophan and carbidopa. , 1980, The New England journal of medicine.

[16]  H. Paulus,et al.  Measurement of clinical change in progressive systemic sclerosis: a 1 year double-blind placebo-controlled trial of N-acetylcysteine. , 1979, Annals of the rheumatic diseases.

[17]  M. Kahaleh,et al.  Endothelial injury in scleroderma , 1979, The Journal of experimental medicine.

[18]  A. Kang,et al.  Evidence for cell-mediated immunity to collagen in progressive systemic sclerosis. , 1976, The Journal of laboratory and clinical medicine.

[19]  P. Cannon,et al.  THE RELATIONSHIP OF HYPERTENSION AND RENAL FAILURE IN SCLERODERMA (PROGRESSIVE SYSTEMIC SCLEROSIS) TO STRUCTURAL AND FUNCTIONAL ABNORMALITIES OF THE RENAL CORTICAL CIRCULATION , 1974, Medicine.

[20]  A. H. Mackenzie.  An appraisal of chloroquine. , 1970, Arthritis and rheumatism.

[21]  G. Rodnan,et al.  Serum antinuclear antibodies in progressive systemic sclerosis (scleroderma). , 1968, Arthritis and rheumatism.